Home/Filings/4/0001209191-23-015753
4//SEC Filing

Lebwohl David 4

Accession 0001209191-23-015753

CIK 0001652130other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 5:15 PM ET

Size

7.3 KB

Accession

0001209191-23-015753

Insider Transaction Report

Form 4
Period: 2023-03-01
Lebwohl David
EVP, Chief Medical Officer
Transactions
  • Award

    Common Stock

    2023-03-01+30,67456,361 total
  • Award

    Stock Option (right to buy)

    2023-03-01+43,34243,342 total
    Exercise: $40.75Exp: 2033-02-28Common Stock (43,342 underlying)
Footnotes (2)
  • [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
  • [F2]This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1
  • filerCIK 0001810882

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 5:15 PM ET
Size
7.3 KB